You just read:

US Rheumatologists Teed Up for Rapid Adoption of BMS' Orencia in Psoriatic Arthritis, Though the Real Game Changer Could Come with the Approval of Pfizer's Xeljanz

News provided by

Spherix Global Insights

Oct 20, 2017, 09:54 ET